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The rat monoclonal antibody LMR-12 was shown earlier to react with a plasma membrane protein, upregulated in multidrug-
resistant cell lines. In this study, we observed distinct LMR-12 staining in 36 out of 55 non-drug-selected tumour cell lines,
including melanomas, renal cell-, colon- and lung carcinomas, whereas in other tumour types, such as leukaemia and ovarian
cancer, LMR-12 staining was generally low or absent. The cDNA encoding the LMR-12 antigen was isolated from a library of the
multidrug-resistant human ﬁbrosarcoma cell line HT1080/DR4 by expression cloning in MOP8 cells. Sequence analysis showed
that the LMR-12 antigen is identical to the major histocompatibility complex class I molecule beta 2-microglobulin (b2-m). The
LMR-12/ b2-m staining results were conﬁrmed by mRNA microarray data from an independent National Cancer Institute study,
as well as by newly obtained reverse transcriptase polymerase chain reaction data. Further analysis of the microarray data
showed that b2-m levels closely reﬂected levels of major histocompatibility complex class I heavy chains and the transporter
associated with antigen processing. Since the ABC transporter associated with antigen processing was previously shown to
contribute to multidrug-resistance, it may very well be that the observed LMR-12/ b2-m levels are secondary to (elevated) levels
of the transporter associated with antigen processing. A perspective arising from the present study is that drug resistant tumour
cells may, by having elevated levels of major histocompatibility complex related molecules, be particular good candidates for
alternative therapeutic therapies, such as cytotoxic T cell mediated immune-therapies.
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Multidrug resistance (MDR, reviewed in Schneider et al, 1999) has
been associated with the overexpression of genes involved in metabo-
lism and transport of various anticancer drugs. The ‘classical’ form of
MDR is associated with the product of the MDR1 gene, P-glycopro-
tein (MDR1 P-gp, ABCB1), reviewed in Ambudkar et al (1999).
MDR1 P-gp is a plasma membrane protein, that acts as an ATP-
dependent efﬂux pump for natural product drugs. MDR1 P-gp over-
expression is particularly prominent in tumour cell lines selected in
vitro by high concentrations of natural product drugs. Subsequently,
in several non-P-gp MDR tumour cell lines high levels of other
members of the ATP-binding cassette (ABC) transporter superfamily
(Higgins, 1992) were identiﬁed: the Multidrug Resistance Protein 1
(MRP1; ABCC1; reviewed in Cole and Deeley (1998) and the Breast
Cancer Resistance Protein (BCRP; ABCG2) (Doyle et al, 1998). Also
other MRP family members (MRP2-6; ABCC2-6) (Kool et al, 1997;
Borst et al, 2000) were identiﬁed to possibly contribute to MDR.
In an ongoing search for proteins involved in drug resistance we
selected monoclonal antibodies (Mabs) against proteins with
elevated levels in non-P-gp MDR cell lines. Immunisation of mice
with the lung cancer cell line SW-1573/2R120 led to the selection
of the LRP-56 Mab (Scheper et al, 1993). Expression cloning of
the corresponding cDNA identiﬁed the Mr 110000 antigen as the
human major vault protein (MVP) (Scheffer et al, 1995). In another
endeavour using rats, we generated a panel of six Mabs reactive with
proteins present at high levels in non-P-gp MDR tumour cell lines,
but low or absent in the corresponding drug-sensitive, parental
tumour cell lines (Flens et al, 1997). One of these Mabs, LMR-5,
was also found to be directed to the MVP molecule, as shown by
staining of MVP cDNA transfected MOP8 cells (Flens et al, 1997).
A second one, the LMR-42 Mab, was shown to react with the
endothelial cell protein C receptor (Scheffer et al, 2002). A third
Mab in the panel, LMR-12, reacted with a plasma membrane
protein of unidentiﬁed molecular weight. The protein had been
found to be upregulated in several MDR cell lines (Flens et al,
1997) and appeared to be widely expressed in normal human tissues.
Pre-labelling the tumour cells with high amounts of LMR-12 anti-
body was unable to increase the intracellular drug accumulation
in the tumour cells (Flens et al, 1997). In this study we examined
the presence of the LMR-12 antigen in a broad panel of drug-unse-
lected human tumour cell lines of the US National Cancer Institute
by immunohistochemical stainings. Furthermore, by expression
cloning using a cDNA library of the human MDR ﬁbrosarcoma cell
line HT1080/DR4, we identiﬁed the antigen of LMR-12.
MATERIALS AND METHODS
Cell lines
A total of 55 cell lines of the National Cancer Institute’s (NCI)
anticancer drug screen panel was obtained and processed as
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www.bjcancer.comdescribed previously (Wu et al, 1992). The panel includes cell
lines derived from cancers of the colon, kidney, lung, breast,
ovary, and brain, as well as melanoma and leukaemia. All other
cell lines used have been described in the literature and are
mentioned in Scheffer et al (2000). The cell lines included the
small cell lung carcinoma cell line GLC4 and its adriamycin-resis-
tant (MRP1 positive) subline GLC4/ADR; the leukaemia cell lines
HL60 and the adriamycin-resistant (MRP1 positive) HL60/ADR
subline; the ﬁbrosarcoma cell line HT1080 and its daunorubicin
resistant subline HT1080/DR4. The polyoma transformed NIH3T3
mouse ﬁbroblast cell line MOP8 (Muller et al, 1984) was used for
transfection experiments.
The resistant sublines were routinely cultured in the presence of
cytotoxic drug until 3–10 days before the experiments. The cell
lines were cultured in RPMI-1640 or Dulbecco’s modiﬁed essential
medium (DMEM; Gibco Europe, Paisley, Scotland) with 10% heat-
inactivated foetal calf serum (Gibco Europe) and 2 mML -gluta-
mine. All cell lines were passed once or twice weekly and
routinely examined for Mycoplasma contamination.
Tumour samples
The panel of 34 human tumours of different histogenetic origins
included (snap frozen) tumours of the intestine, stomach, testis,
prostate, lung, pancreas, bladder, adrenal gland, cervix, neurologic
tissue, breast, ovary, kidney and melanoma.
Immunohistochemistry
Cytocentrifuge preparations of tumour cell lines or frozen sections
of tumour samples were air-dried overnight and ﬁxed for 7 min in
acetone. The slides were incubated for 1 h with LMR-12 (1:500)
or isotype matched rat Ig in PBS containing 1% BSA. Additional
control stainings were done with the W6/32 Mab. This mouse
Mab is a broadly used pan-HLA class I-reactive monoclonal anti-
body that recognises a conformational epitope dependent on
association between heavy chains and b2-m (Barnstable et al,
1978; Tran et al, 2001). MAb binding was detected using biotiny-
lated rabbit anti-rat IgG (1:100; Dako, Copenhagen, Denmark) or
anti-mouse IgG (1:150; Dako) and streptavidin conjugated to
horseradish peroxidase (1:500; Zymed, San Francisco, CA, USA).
Colour development was with 0.02% (w v
71) amino-ethyl-carba-
zole and 0.02% (v v
71)H 2O2 in 0.1 M sodium acetate buffer,
pH 5.0. Evaluation was done on coded slides to avoid bias in scor-
ing. As used before for this type of analysis (Izquierdo et al, 1996a),
a semiquantitative ‘staining index’ was calculated as the product of
the fraction of positive cells and the average staining intensity esti-
mated on a scale from 0 (negative) to 3 (very strong positive). At
least three tests for each cell line were used for calculation of the
average staining index. The parental GLC4 and MDR GLC4/ADR
cell lines served as controls for LMR-12 staining.
FACS analysis
One hundred ml of cell suspensions at a concentration of 1610
6
viable cells per ml were incubated with 10 mg LMR-12, W6/32,
control Mab or rabbit polyclonal anti b2-m for 1 h at room
temperature. Antibody binding was detected using FITC-labelled
rabbit-anti-rat serum (1:100, Dako), -anti-mouse serum (1:100,
Dako) or swine-anti-rabbit serum (1:100, Dako) for another hour
at room temperature. The samples were analysed on a FACS-Star
ﬂow cytometer (Becton-Dickinson, San Jose, CA, USA).
cDNA library and isolation of the LMR-12 cDNA clone
Previously, a cDNA-library was derived from mRNA isolated from
the human MDR ﬁbrosarcoma cell line HT1080/DR4 (Scheffer et
al, 1995). Brieﬂy, a size-fractionated (42 kbp) oligo d(T) primed
cDNA-library was constructed in the shuttle vector pCDM8 using
non-self complementary BstXI adaptors (Invitrogen, Leek, The
Netherlands). Transformation of the library into the Escherichia coli
strain MC1061/P3 by electroporation yielded approximately
100000 primary colonies. These were divided into 10 sublibraries
of 10000 colonies each.
Bacterial subpools were grown overnight in Luria-Bertani
medium, supplemented with 7.5 mgm l
71 tetracycline (Boehringer
Mannheim B.V., Almere, The Netherlands), and 12.5 mgm l
71
ampicillin (Sigma Chemie, Bornem, Belgium). Plasmid DNA,
containing cDNA inserts, was isolated from minipreparations of
the bacterial sublibraries by alkaline lysis. MOP8 cells were trans-
fected with isolated plasmid DNA using the DEAE-dextran
method (Promega Corporation, Leiden, The Netherlands) as
described by Aruffo and Seed (1987). Transfected MOP8 cells were
allowed to grow for 72 h, and after trypsinization cytospins were
prepared. These cytospins were air-dried overnight, ﬁxed in
100% acetone for 7 min and stained with LMR-12 (1:500) to
detect transiently expressed protein as described above. A colony
containing the cDNA coding for the LMR-12 antigen was isolated
by screening progressively smaller pools of bacterial colonies.
cDNA sequence analysis
The LMR-12 cDNA clone was sequenced using the dideoxy Termi-
nator Cycle Sequencing Kit on an automated 373A DNA sequencer
(Applied Biosystems Benelux B.V., Maarsen, The Netherlands).
Sequencing was performed in both orientations to conﬁrm the
nucleotide sequence. The data were collected and analysed using
373A computer software.
RNA isolation and RT–PCR
Total RNA was isolated using the RNeasy 96 kit and the QIAvac
vacuum manifold (Qiagen, Valencia, CA, USA) per manufacturer’s
protocol. Total RNA samples were quantitated using the ﬂuores-
cent Ribogreen RNA quantitation reagent kit (Molecular probes)
and RNA was stored at 7708C until use for RT–PCR.
The RT–PCR reactions were measured with the ABI Prism
7700 Sequence Detection System using TaqMan one-step RT–
PCR SYBR green PCR master mix in 50 ml reactions using 5 ng
total RNA per reaction. Primers for b2-m were designed with
Primer Express software (PE Biosystems, Foster City, CA, USA;
forward primer: GGCTATCCAGCGTACTCCAAAG, reverse
primer: CAACTTCAATGTCGGATGGATG). GAPDH was used
as an endogenous control (forward primer: GAAGGTGAAGGT-
CGGAGTC, reverse primer: GAAGATGGTGATGGGATTTC).
Primer concentrations for b2-m and GAPDH were 600 and
100 nM respectively. Thermocycler parameters were 30 min at
488C, 10 min at 958C and 40 PCR cycles of 15 s at 958C and
1 min at 608C. All RNA samples were tested in triplicate PCR
reactions. Data was analysed using the comparative CT method
(Perkin Elmer, user bulletin #2) and b2-m was normalysed to a
calibrator cell line (HCC-2998).
Correlative and COMPARE analysis
Using SPSS 9.0 statistical software, two-tailed Pearson correlation
coefﬁcients (PCC) were calculated between (LMR-12) immunohis-
tochemical staining data, microarray data from Ross et al (2000)
and Scherf et al (2000) (available at the NCI Developmental Ther-
apeutics Program website (http://dtp.nci.nih.gov)), and b2-m
mRNA data from the RT–PCR.
The COMPARE program of the NCI Developmental Therapeu-
tics Program was used to examine the correlation between the
LMR-12 staining results and sensitivity for compounds tested,
and with basal patterns of gene expression in the 55 cell lines
measured by cDNA microarray.
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Frequent LMR-12 staining in tumour cell lines
As reported previously (Flens et al, 1997), LMR-12 staining was
observed in a broad panel of MDR cell lines, with higher levels
in the resistant sublines. Among these cell lines are the paired
parental and resistant cell lines GLC4 and GLC4/ADR, the HL60
and HL60/ADR and the HT1080 and HT1080/DR4 cell line. To
further study the prevalence of the LMR-12 antigen in a panel of
drug-unselected human tumour cell lines of the US National
Cancer Institute’s anticancer drug screening program, cytospins
of these cell lines were examined for LMR-12 expression. In 36
out of 55 tumour cell lines of the panel LMR-12 staining was
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Table 1 Staining indices for MDR1 P-gp, MRP1, MVP, LMR-12/b2-m, relative LMR-12 staining values and b2-m mRNA values in the NCI panel of human
cancer cell lines
Cell line Tumour type MDR1 P-gp MRP1 MVP LMR-12/b2-m rel. LMR-12 staining b2-m microarray rel. b2-m RT–PCR
MALME-3M Melanoma * * ** *** 2.04 0.07 70.06
M14 Melanoma * ** * * * 1.04 0.21 1.53
SK-MEL-5 Melanoma * ** ** ** 0.44 70.12 71.08
SK-MEL-28 Melanoma * * * * ** 0.64 70.09 72.97
UACC-257 Melanoma * * * * ** 0.24 70.19 71.82
M19-MEL Melanoma * ** * * ND ND ND
SK-MEL-2 Melanoma ** * * * * 70.06 0.22 2.12
UACC-62 Melanoma * ** * * * * 70.56 0.06 4.83
LOX Melanoma * * ** * 70.91 70.18 71.68
TK-10 Renal * ** ** *** 2.04 0.17 73.04
RXF-393 Renal * * * * ** 0.94 0.40 3.18
ACHN Renal * * ** * 70.11 0.13 2.49
RXF-631 Renal ** * ** * ND ND ND
SN12 Renal ** * ** * 70.06 70.05 72.07
A498 Renal * ND ND * 70.36 70.30 0.99
786-0 Renal * * ** * * 70.96 0.12 1.49
COLO-205 Colon * * ** *** *** 2.04 0.30 0.13
HCT-116 Colon * * ** *** *** 2.04 70.18 1.10
HT29 Colon ** ** ** 0.34 0.35 2.54
KM20L2 Colon * ** * * ND ND ND
SW-620 Colon * * * * * * 70.36 70.24 71.95
KM12 Colon ** * * * 70.41 0.13 1.49
HCC-2998 Colon * ** ** * * 70.56 70.57 76.04
HCT-15 Colon ** * * * * 70.96 70.62 72.78
DLD-1 Colon * ** * * ND ND ND
HOP-62 Lung * ** ** *** 2.04 70.11 71.86
NCI-H226 Lung * * ** *** 2.04 0.48 6.29
DMS-114 SCLC * * * * *** ND ND ND
HOP-92 Lung * ND * * ** 0.74 0.42 70.29
LXFL-529L Lung * ** * * ND ND ND
EKVX Lung * * * ** * 70.41 0.10 6.79
NCI-H23 Lung ** * * * * * 70.71 70.26 71.16
HOP-18 Lung * ND ** * ND ND ND
A549 Lung ** * * 70.96 70.35 73.06
NCI-H522 Lung ** * ** 70.96 70.49 71.24
DMS-273 SCLC ** * ** ND ND ND
SNB-75 CNS ** * * *** 1.29 0.48 2.40
SF-539 CNS ** * * *** 1.89 0.66 3.29
SF-295 CNS * ** * ** 0.24 0.25 0.42
XF-498 CNS * ND * * * * ND ND ND
SF-268 CNS * * ** 70.96 0.19 2.00
SNB-19 CNS ** * * 70.96 0.34 2.65
SNB-78 CNS * ** * * ND ND ND
RPMI 8226 Leukemia ND * * *** 1.74 0.59 4.85
HL-60 Leukemia ND * * * * * 70.36 0.20 70.98
CEM Leukemia ND * ** 70.96 0.14 72.69
K-562 Leukemia ND * ** 70.96 0.14 74.02
SR Leukemia ND * ** 70.96 0.42 0.72
MOLT-4 Leukemia ND ** * 70.96 70.02 73.81
OVCAR-5 Ovary ** * ** ** 0.04 0.15 2.49
OVCAR-4 Ovary * * ** ** * * 70.86 70.02 73.03
SK-OV-3 Ovary * ** * * 70.71 0.10 0.63
OVCAR-8 Ovary * * ** ** * 70.96 71.00 70.83
IGROV1 Ovary ** * ** * 70.96 70.20 71.62
OVCAR-3 Ovary ** * ** 70.96 70.34 73.47
The staining data of MDR1 P-gp, MRP1 and MVP are given for comparison (MDR1 P-gp adapted from Wu et al (1992), MRP1 and MVP adapted from Izquierdo et al (1996a)).
The staining indices were calculated as the product of the fraction of positive cells and staining intensity, and presented as follows: 0=*, 0–0,5=* * , 0,5–1,0=*, 1,0–2,0=**,
2,0–3,0=***, ND=not determined. The b2-m microarray data are adapted from Ross et al (2000) and Scherf et al (2000). The RT–PCR data were normalised to a
calibrator cell line (HCC-2998). The relative expression data are equivalent to ‘meangraphs’; expression results were averaged and each value is expressed as a function of
the average value.
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MDR1 P-gp, MRP1 and MVP are given for comparison (MDR1
P-gp adapted from Wu et al (1992), MRP1 and MVP adapted from
Izquierdo et al (1996a)). LMR-12 positive staining was particularly
evident in distinct tumour types i.e. melanomas (seven out of nine
cell lines), renal cell carcinomas (six out of seven), colon carcino-
mas (six out of nine cell lines) and lung carcinomas (six out of 11
cell lines). In leukemia and ovarian cancers generally low expres-
sion was observed. LMR-12 staining was frequently accompanied
by MVP-, MRP1-, and/or MDR1 P-gp staining, but only with
MVP staining a signiﬁcant correlation was observed (r=0.515,
P50.001).
b b2-m is the LMR-12 antigen
As reported previously (Flens et al, 1997), Western blot experi-
ments did not give information on the nature of the cognate
antigen of the LMR-12 Mab, not even when
125Iodine-labelled
LMR-12 was used in the experiments. Also, immunoprecipitation
experiments did not reveal the antigen. Therefore, the expression
cloning system that had succesfully been used to identify the nature
of the LRP-56 Mab (Scheffer et al, 1995) was also used here. MOP8
cells were transiently transfected with pCDM8 vector, containing
cDNA inserts of the MDR ﬁbrosarcoma cell line HT1080/DR4
and screened for LMR-12 immunoreactivity. In the primary screen-
ing, MOP8 cells transfected with cDNAs from one of the
sublibraries showed one single LMR-12 immunoreactive MOP8 cell
among approximately 30610
6 cells. The coding cDNA clone was
isolated from the sublibrary after several cycles of screening of
MOP8 cells transfected with cDNA’s from progressively smaller
pools of bacterial colonies for transiently expressed antigen.
Sequence analysis of both ends of the LMR-12 cDNA, and data-
base searches with the obtained sequence information revealed that
the LMR-12 antigen is the human major histocompatability
complex (MHC) protein b2-m.
LMR-12/b2-m staining data correlates with mRNA data
To conﬁrm the expression data on b2-m in the cell line panel, the
correlation between the LMR-12/ b2-m staining data and microar-
ray data on mRNA levels for b2-m was examined. Ross et al (2000)
and Scherf et al (2000) have reported microarray data on approxi-
mately 8000 genes in the cell lines of the NCI panel, including b2-
m. These data are available via http://dtp.nci.nih.gov. From a total
of 45 cell lines, both protein and mRNA data could be compared.
The analysis showed a moderate, but highly signiﬁcant correlation
(Tables 1 and 2 and Figure 2) for b2-m protein and mRNA data in
these studies.
To further explore the correlation between LMR-12/ b2-m
protein and mRNA data, a light-cycle RT–PCR was performed
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COLO-205 SN12 SR
Figure 1 LMR-12 staining of cytospins of cell lines in the NCI cell line panel (see also Table 1); COLO-205 (colon, strongly positive), SN12 (renal, weakly
positive) and SR (leukaemia, negative). Colour development was with 0.02% (w v
71) amino-ethyl-carbazole and 0.02% (v v
71)H 2O2.
Table 2 Pearson correlation coefﬁcients for HLA-A, HLA-B, b2-m and TAP1 mRNA microarray analyses, and b2-m RT–PCR and
LMR-12/b2-m staining results
HLA-A array HLA-B array b2-m array b2-m RT–PCR LMR-12 staining TAP1 array
HLA-A array PCC 1.000 0.796 0.402 0.435 0.494 0.614
p 50.001 0.001 0.003 0.001 50.001
n6 0 6 0 6 0 4 5 4 5 5 9
HLA-B array PCC 0.796 1.000 0.339 0.389 0.434 0.688
p 50.001 0.008 0.008 0.003 50.001
n6 0 6 0 6 0 4 5 4 5 5 9
b2-m array PCC 0.402 0.339 1.000 0.606 0.445 0.441
p 0.001 0.008 50.001 0.002 50.001
n6 0 6 0 6 0 4 5 4 5 5 9
b2-m RT–PCR PCC 0.435 0.389 0.606 1.000 0.318 0.398
p 0.003 0.008 50.001 0.033 0.007
n4 5 4 5 4 5 4 5 4 5 4 4
LMR-12 staining PCC 0.494 0.434 0.445 0.318 1.000 0.316
p 0.001 0.003 0.002 0.033 0.037
n4 5 4 5 4 5 4 5 4 5 4 4
TAP1 array PCC 0.614 0.688 0.441 0.398 0.316 1.000
p 50.001 50.001 50.001 0.007 0.037
n5 9 5 9 5 9 4 4 4 4 5 9
PCC=Pearson correlation coefﬁcient; p=signiﬁcance, signiﬁcant when P50.05; n=number of samples.
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the cell lines, normalised to a calibrator cell line (HCC-2998), also
showed a moderate, but signiﬁcant correlation with the LMR-12/
b2-m staining data (Tables 1 and 2 and Figure 2). Correlation
between RT–PCR data and microarray data was highly signiﬁcant
(Tables 1 and 2 and Figure 2).
To further examine the correlation of the LMR-12/ b2-m data
with MHC class I associated molecules, statistical analyses were
done on microarray data available for these molecules. (Highly)
signiﬁcant correlations were observed for both LMR-12/ b2-m
staining data and b2-m mRNA data with microarray data for the
MHC class I heavy chains HLA-A and HLA-B, as well as with
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
malme-3m
m14
sk-mel-5
sk-mel28
uacc-257
sk-mel-2
uacc-62
lox imvi
tk-10
rxf 393
achn
sn12c
a498
786-0
colo205
hct-116
ht29
sw620
km12
hcc-2998
hct15
hop-62
nci-h226
hop-92
ekvx
nci-h23
a549/atcc
nci-h522
snb-75
sf-539
sf-295
sf-268
snb-19
rpmi-8226
hl-60(tb)
ccrf-cem
k-562
sr
molt-4
ovcar-5
ovcar-4
sk-ov-3
ovcar-8
igrov1
ovcar-3
malme-3m
m14
sk-mel-5
sk-mel28
uacc-257
sk-mel-2
uacc-62
lox imvi
tk-10
rxf 393
achn
sn12c
a498
786-0
colo205
hct-116
ht29
sw620
km12
hcc-2998
hct15
hop-62
nci-h226
hop-92
ekvx
nci-h23
a549/atcc
nci-h522
snb-75
sf-539
sf-295
sf-268
snb-19
rpmi-8226
hl-60(tb)
ccrf-cem
k-562
sr
molt-4
ovcar-5
ovcar-4
sk-ov-3
ovcar-8
igrov1
ovcar-3
malme-3m
m14
sk-mel-5
sk-mel28
uacc-257
sk-mel-2
uacc-62
lox imvi
tk-10
rxf 393
achn
sn12c
a498
786-0
colo205
hct-116
ht29
sw620
km12
hcc-2998
hct15
hop-62
nci-h226
hop-92
ekvx
nci-h23
a549/atcc
nci-h522
snb-75
sf-539
sf-295
sf-268
snb-19
rpmi-8226
hl-60(tb)
ccrf-cem
k-562
sr
molt-4
ovcar-5
ovcar-4
sk-ov-3
ovcar-8
igrov1
ovcar-3
–1.50 –1.00 –0.50 0.00 0.50 1.00 1.50 2.00 2.50 –8.00 –6.00 –4.00 –2.00 0.00 2.00 4.00 6.00 8.00 –1.5 –1 –0.5 0 0.5 1
LMR-12 staining
in 45 cell lines of the anticancer
drug screen
–8.00 –6.00 –4.00 –2.00 0.00 2.00 4.00 6.00 8.00
RT-PCR data on b2-m
in 45 cell lines of the anticancer
drug screen
Microarray data on b2-m
in 45 cell lines of the anticancer
drug screen
Figure 2 Meangraphs of LMR-12 staining, b2-m RT–PCR data and b2-m microarray data in 45 cell lines of the anticancer drug screen. The RT–PCR data
were normalised to a calibrator cell line (HCC-2998). The b2-m microarray data are available at http://dtp.nci.nih.gov. The meangraphs were made from
relative expression data; expression results were averaged and each value was expressed as a function of the average value (see Table 1). Correlations
calculated from these data are presented in Table 2.
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(Table 2).
LMR-12/b2-m staining correlates with W6/32 MHC class I
staining
To further conﬁrm the association of LMR-12/ b2-m staining with
MHC class I heavy chain, we FACS analysed the staining of LMR-
12/ b2-m, the anti-MHC class I Mab W6/32 and a polyclonal anti
b2-m antiserum in paired parental and MDR cell lines. The results
observed with the latter two reagents were highly comparable to
the LMR-12 results. Elevated staining of all three antisera was
observed in the GLC4/ADR cells and in the HL60/ADR cells
compared to their parental cell lines (Figure 3).
In a panel of 34 human tumours of different histogenetic origin,
clear LMR-12/ b2-m staining was observed in *90% of the
tumour samples, while the surrounding normal tissue always
stained positive. The staining pattern of LMR-12/ b2-m was closely
paralleled by W6/32 staining (Figure 4).
COMPARE analysis
When the LMR-12/ b2-m staining values for the tumour cell lines
were utilised as a ‘seed’ pattern for the COMPARE program, no
correlations greater than 0.46 were observed for anticancer agents
tested. Extensions of these analyses to the whole synthetic database
showed no correlations greater than 0.6 and no clear chemical
structural theme could be observed in the top ranked compounds.
Application of the COMPARE analysis to the molecular targets
database yielded MVP as the second ranked pattern. The ﬁrst
ranked pattern was the BCL2-antagonist of cell death (BAD). While
these were the best correlations observed, they were not particularly
strong, with Pearson correlation coefﬁcients (PCC) in the 0.3–0.4
range. MRP1 also showed up in this analysis, ranked at position 17
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W6/32 Poly rabbit b2-m
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GLC4 cells
MDR subline GLC4/ADR cells
Figure 3 FACS analysis of GLC4 and MDR subline GLC4/ADR cells with
control Mab, LMR-12, W6/32 and rabbit polyclonal anti b2-m. The different
anti-MHC class I anti sera show similarly positive signals on the GLC4 cells,
which are equally increased on the MDR subline GLC4/ADR. Antibody
binding was detected using FITC-labelled rabbit-anti-rat serum, -anti-mouse
serum or swine-anti-rabbit serum. The samples were analysed on a FACS-
Star ﬂow cytometer.
LMR-12/ b2-m W6/32 HLA class I Control
Small intestine
Lung cancer
Figure 4 Staining of frozen sections of tumour samples with LMR-12, W6/32 and control Mab. Upper panel: small intestinal cancer samples (showing only
staining in the surrounding tissue). Lower panel: lung cancer samples (showing staining in the tumour cells and in the surrounding tissue). In the two panels a
similar staining pattern is observed for both LMR-12/ b2-m and W6/32 HLA class I molecules. Colour development was with 0.02% (w v
71) amino-ethyl-
carbazole and 0.02% (v v
71)H 2O2.
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S-transferase (GST) pi with a PCC of 0.454.
Comparison to the microarray database yielded several unfami-
liar genes in the top 10, but also two MHC class I molecules, F and
A, at position 11 and 12, respectively, and with PCCs of around
0.5. Also, b2-m showed up in the analysis, at position 26, with a
PCC of 0.47.
DISCUSSION
Staining with the rat antibody LMR-12 was reported to be upregu-
lated in a broad panel of MDR cell lines (Flens et al, 1997). In this
study we found that the LMR-12 antigen is also present in 36 out of
55 samples of a panel of drug-unselected primary tumour cells.
Staining was particularly evident in distinct tumour cell types that
are in general considered as refractory to chemotherapy, i.e. mela-
nomas, renal cell-, colon- and lung carcinomas. Tumour cells
considered more sensitive to chemotherapy, such as leukaemia
and ovarian carcinoma showed only low staining levels. LMR-12
staining was never exclusive and correlated signiﬁcantly with
MVP staining, but not with MRP1 or MDR1 P-gp staining. Collec-
tively, these results suggested the potential relevance of the cognate
antigen in resistance of tumour cells to cytostatic drug exposure.
Considering that drug resistance continues to represent a major
obstacle in clinical cancer treatments, we set out to identify the anti-
gen recognised by the LMR-12 Mab. As conventional Western blot
and immunoprecipitation techniques had proven unsuccesful to
give information on the identity of the antigen of this Mab, we used
an eukaryotic expression cloning procedure. The LMR-12 MAb was
used as a probe to detect transiently expressed protein in transfected
MOP8 cells and to isolate the cDNA encoding the antigen.
Sequence analysis and database searches showed that the LMR-
12 antigen has no homology with ABC transporter proteins
involved in MDR. Instead, the protein turned out to be identical
to the human MHC class I molecule b2-m. The Mr 12000 b2-m
associates with MHC class I heavy chains to form class I human
leukocyte antigen (HLA) complexes.
When comparing our LMR-12/ b2-m staining data in the NCI
cell line panel to independent, previously reported b2-m mRNA
microarray data and to newly obtained RT–PCR mRNA data,
we observed moderate, but signiﬁcant correlations between
protein and mRNA data. The RT–PCR data correlated highly
signiﬁcantly with the microarray data. As yet, only a few reports
have been published on the correlation between mRNA and
protein levels in cells and tissues, whereas none has correlated
microarray data with RT–PCR data. Similar to our observations,
Anderson and Seilhamer (1997) found a correlation coefﬁcient of
0.48 for mRNA levels and proteins expressed in human liver.
These, acceptable, but non-perfect correlations indicate that
post-transcriptional regulation of gene expression is a frequent
phenomenon in higher organisms and very likely holds true
for b2-m as well. Furthermore, b2-m transcript levels appeared
to vary considerably in individual cell lines, making b2-m a poor
candidate for standardising mRNA levels as detected by e.g. RT–
PCR. Although similar ﬁndings were already reported by Finne-
gan et al (1993), still many researchers erroneously choose b2-m
as a standard housekeeping gene.
The observed signiﬁcant correlation between microarray data
and protein data as well as mRNA data obtained by RT–PCR,
indicates that publicly accessible databases containing microarray
data for large numbers of genes can be an important valid informa-
tion source for researchers.
Further accession of the microarray database to correlate our b2-
m results to reported microarray data on MHC related molecules
showed that both b2-m staining and mRNA data (highly) signiﬁ-
cantly correlated with mRNA data for MHC class I heavy chains
and TAP1. The connection of the LMR-12/ b2-m data with
MHC class I heavy chains was also conﬁrmed by staining results
with the W6/32 Mab both in FACS experiments and immunohis-
tochemical stainings of human tumour sections. Also in the
COMPARE analysis to the microarray database MHC class I mole-
cules turned up at high positions in the list. When compared to
molecular targets, interesting molecules such as GST pi, BAD
and the MDR marker MVP turned up, but no high correlations
were observed for anticancer agents tested.
As b2-m itself has no characteristics of a transporter protein,
it seems very unlikely that the protein itself plays a causal role
in the MDR phenotype. Still, upregulation of MHC related
molecules in MDR cells was already observed in previous
studies. Iguchi et al (2001) noted upregulation of MHC class
I molecules, including b2-m, in gastric- and colon cancer cell
lines after treatment with the plant polysaccharide PSK, which
was examined for anti-tumour effects. Furthermore, in a study
to examine the possible contribution of the ABC transporter
associated with antigen processing (TAP) to MDR, we showed
that in our panel of MDR cell lines elevated TAP levels were
paralleled by elevated levels of MHC class I molecules (Izquier-
do et al, 1996b). The TAP molecule plays a major role in
MHC class I-restricted antigen presentation by mediating
peptide translocation over the endoplasmic reticulum membrane.
In the same study a moderate contribution of TAP to MDR
was demonstrated by transfection of the TAP genes into TAP-
deﬁcient lymphoblastoid T2 cells, resulting in low level resis-
tance to etoposide, vincristine and doxorubicin. Therefore, it
seems valid to conclude that the observed elevated levels of
b2-m in this study most likely are the consequence of upregula-
tion of TAP. Recently, the antigen of LMR-42, another MDR-
related Mab originating from the same study as the LMR-12
Mab (Flens et al, 1997), was identiﬁed as the endothelial cell
protein C receptor (EPCR). This type 1 transmembrane glyco-
protein is also a member of the MHC superfamily (Scheffer
et al, 2002). In contrast to these ﬁndings of upregulated
MHC related molecules, many studies have reported on down-
regulation or loss of expression of MHC class I related
molecules in malignant cells (Kaklamanis et al, 1995; Korkolo-
poulou et al, 1996; Keskinen et al, 1997; Gudmundsdottir et
al, 2000; Kamarashev et al, 2001; Palmisano et al, 2001). Ogret-
men et al (1998) even reported the loss or decreased expression
of b2-m in drug-resistant sublines of MCF-7 and HL60 cells,
controlled by post-transcriptional mechanisms. These authors
also reported that the partial inhibition of b2-m by antisense
RNA resulted in 2–3-fold decreased sensitivity of MCF-7 cells
to doxorubicin and mAMSA. An explanation for these opposing
results may be, partially, found in utilising other (sub) lines of
cell lines and differences in culture conditions. MHC class I
levels may be inﬂuenced by differences in culture medium
components, and the presence or absence of stimulating cyto-
kines such as interferon gamma (Keskinen et al, 1997). From
a different perspective the obtained results may be interesting
for therapeutic treatments as well. Drug resistant tumour cells
may, by having elevated levels of MHC related molecules, be
particular good candidates for alternative therapies, such as
cytotoxic T cell mediated immune-therapies.
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